Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation

References

• Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176.
   PubMed Web of Science ®Google Scholar
• Bruno S, Zuin M, Crosignani A, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009;104:1147–1158.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
   PubMed Web of Science ®Google Scholar
• Bukh J. The history of hepatitis C virus (HCV): basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol. 2016;65(1 Suppl):S2–S21.
   Web of Science ®Google Scholar
• dst.dk. [Internet]. Denmark: Danmarks Statistik; [cited 2017 Feb 20]. Available from: https://www.dst.dk/.
   Google Scholar
• Christensen PB, Hay G, Jepsen P, et al. Hepatitis C prevalence in Denmark – an estimate based on multiple national registers. BMC Infect Dis. 2012;12:178.
   PubMed Web of Science ®Google Scholar
• Corbet S, Bukh J, Heinsen A, et al. Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. J Clin Microbiol. 2003;41:1091–1100.
   PubMed Web of Science ®Google Scholar
• Solund C, Krarup H, Ramirez S, et al. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations. PLoS One. 2014;9:e113034.
   PubMed Web of Science ®Google Scholar
• Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–648.
   PubMed Web of Science ®Google Scholar
• Naggie S, Muir AJ. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs. Annu Rev Med. 2017;68:345–358.
   PubMed Web of Science ®Google Scholar
• Bach TA, Zaiken K. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1–4 in an ambulatory care setting. Am J Health Syst Pharm. 2017;74(5 Supplement 1):S1–S9.
   Web of Science ®Google Scholar
• Su F, Beste LA, Green PK, et al. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. Eur J Gastroenterol Hepatol. 2017;29(6):686–693.
   PubMed Web of Science ®Google Scholar
• Calleja JL, Crespo J, Rincon D, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort. J Hepatol. 2017;66(6):1138–1148.
   PubMed Web of Science ®Google Scholar
• Bhamidimarri KR, Satapathy SK, Martin P. Hepatitis C Virus and Liver Transplantation. Gastroenterol Hepatol (N Y). 2017; 13:214–220.
   PubMedGoogle Scholar
• Hansen N, Obel N, Christensen PB, et al. Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study. J Viral Hepat. 2009;16:659–665.
   PubMed Web of Science ®Google Scholar
• Weis N, Thomsen RW. The Danish Database for Hepatitis B and C. Ugeskr Laeger. 2012;174:2521.
   PubMedGoogle Scholar
• Bedossa P, Poynard T. The METAVIR Cooperative Study Group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology. 1996;24:289–293.
   PubMed Web of Science ®Google Scholar
• Christiansen KM, Mossner BK, Hansen JF, et al. Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study. PLoS One. 2014;9:e111912.
   PubMed Web of Science ®Google Scholar
• Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013–1021.
   PubMed Web of Science ®Google Scholar
• Dalgard O, Weiland O, Noraberg G, et al. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study. PLoS One. 2017;12:e0179764.
   PubMed Web of Science ®Google Scholar
• Danish Society for Infectious Diseases, Gastroenterology and Hepatology. Treatment of hepatitis B virus and hepatitis C virus infection 2014 (in Danish).
   Google Scholar
• Danish Society for Infectious Diseases, Gastroenterology and Hepatology. Treatment of hepatitis B virus and hepatitis C virus infection 2015 (in Danish).
   Google Scholar
• Backus LI, Boothroyd DB, Phillips BR, et al. Pretreatment assessment and predictors of hepatitis C virus treatment in US veterans coinfected with HIV and hepatitis C virus. J Viral Hepat. 2006;13:799–810.
   PubMed Web of Science ®Google Scholar
• Yau AH, Lee T, Ramji A, et al. Rate, delay and predictors of hepatitis C treatment in British Columbia. Can J Gastroenterol Hepatol. 2015;29:315–320.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97–104.
   PubMed Web of Science ®Google Scholar
• Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136:288–292.
   PubMed Web of Science ®Google Scholar
• Restrepo A, Johnson TC, Widjaja D, et al. The rate of treatment of chronic hepatitis C in patients co-infected with HIV in an urban medical centre. J Viral Hepat. 2005;12:86–90.
   PubMed Web of Science ®Google Scholar
• Seo KI, Yun BC, Li WJ, et al. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study. Clin Mol Hepatol. 2017;23:74–79.
   PubMed Web of Science ®Google Scholar
• Boglione L, Mornese PS, De NA, et al. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study. J Viral Hepat. 2017;24(10):850–857.
   PubMed Web of Science ®Google Scholar
• Rowan PJ, Tabasi S, Abdul-Latif M, et al. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol. 2004;38:530–534.
   PubMed Web of Science ®Google Scholar
• Le LC, Guillygomarc'h A, Danielou H, et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. J Hepatol. 2012;56:334–340.
   PubMedGoogle Scholar
• Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy. Ann Intern Med. 2016;165:625–634.
   PubMed Web of Science ®Google Scholar
• Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2017;22(4):307–312.
   Web of Science ®Google Scholar
• Bajis S, Dore GJ, Hajarizadeh B, et al. Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: a systematic review. Int J Drug Policy. 2017;47:34–46.
   PubMed Web of Science ®Google Scholar
• Peters L. Decentralised HCV shared care: the SACC Project. [Internet]. Denmark: INHSU 2016; [cited 2017 August 8]. Available from: https://www.eiseverywhere.com/file_uploads/2e5e810198096eef9bceab8c2c12961c_INHSU16_LarsPeters_Abstract.pdf
   Google Scholar
• Sogni P, Gilbert C, Lacombe K, et al. All-oral direct-acting antiviral regimens in HIV/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANRS CO13-HEPAVIH Cohort. Clin Infect Dis. 2016;63:763–770.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.
   PubMed Web of Science ®Google Scholar
• Werner CR, Schwarz JM, Egetemeyr DP, et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: efficacy, safety, and predictors of SVR12. World J Gastroenterol. 2016;22:8050–8059.
   PubMed Web of Science ®Google Scholar
• Arias A, Aguilera A, Soriano V, et al. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir Ther. 2017;22(4):307–312.
   Web of Science ®Google Scholar